AIM ImmunoTech Expands Ampligen Patent Protection in Europe and U.K. Through 2041
OCALA, Fla., Sept. 2, 2026 AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharmaceutical company developing Ampligen® (rintatolimod), announced that...
cancer
Advertisement
Daiichi Sankyo Begins Phase 1 Trial of CD25 ADC DS1025
Tokyo, Japan – August 27, 2026 Daiichi Sankyo has entered a new phase of oncology development with the first...
Medicenna Advances MDNA11 and Bizaxofusp Clinical Programs
TORONTO and HOUSTON, August 14, 2026 Medicenna Therapeutics Corp. reported its first-quarter fiscal 2027 financial results and provided a...
Eikon Therapeutics Selects EIK1001 Dose for Phase 2/3 Melanoma Trial
MILLBRAE, Calif., August 11, 2026 Eikon Therapeutics announced the selection of a 0.60 mg/m² dose of EIK1001 for patients...
Artelo Biosciences Advances ART12.11 Following CBD Research Review
Solana Beach, Calif., July 22, 2026 Artelo Biosciences announced the publication of a peer-reviewed review article in the British...
Advertisements
MaaT Pharma to Seek EMA Re-Examination for Xervyteg After CHMP Rejection
LYON, France, June 26, 2026 MaaT Pharma announced plans to request a re-examination of the European Medicines Agency (EMA)...
Boston Scientific to Acquire Nalu Medical for Pain Therapy Expansion
Marlborough, MA – October 17, 2025 – Boston Scientific Corporation announced that it has entered into a definitive agreement...
FDA Fast Tracks Enterome’s OncoMimics™ Cancer Immunotherapy EO2463
Paris, France – October 16, 2025 – The U.S. Food and Drug Administration (FDA) has granted Fast Track designation...
Advertisement
